A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061-Reference-Cited by-同舟云学术

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061

Published:2014-01-28 Issue:8 Volume:120 Page:1194-1202
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Rudek Michelle A.¹,Moore Page C.²,Mitsuyasu Ronald T.³,Dezube Bruce J.⁴,Aboulafia David⁵,Gerecitano John⁶,Sullivan Ryan⁷,Cianfrocca Mary E.⁸,Henry David H.⁹,Ratner Lee¹⁰,Haigentz Missak¹¹,Dowlati Afshin¹²,Little Richard F.¹³,Ivy Susan Percy¹²,Deeken John F.¹⁴

Affiliation:

1. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University; Baltimore Maryland

2. Department of Biostatistics; University of Arkansas for Medical Sciences; Little Rock Arkansas

3. Department of Medicine, Center for Clinical AIDS Research and Education (CARE Center); University of California at Los Angeles; Los Angeles California

4. Division of Hematology/Oncology; Beth Israel Deaconess Medical Center, Harvard Medical School; Boston Massachusetts

5. Division of Hematology and Oncology; Virginia Mason Medical Center, University of Washington; Seattle Washington

6. Lymphoma Service, Department of Medicine; Memorial Sloan-Kettering Cancer Center; New York New York

7. Massachusetts General Hospital Cancer Center; Boston Massachusetts

8. Northwestern University; Chicago Illinois

9. Department of Medicine; Pennsylvania Hospital; Philadelphia Pennsylvania

10. Division of Oncology, Department of Medicine; Washington University School of Medicine; St Louis Missouri

11. Division of Oncology, Department of Medicine; Albert Einstein College of Medicine/Montefiore Medical Center; Bronx New York

12. Department of Medicine; Case Comprehensive Cancer Center; Cleveland Ohio

13. Cancer Therapy Evaluation Program, National Cancer Institute; National Institutes of Health; Washington DC

14. Division of Medical Oncology/Hematology; Inova Comprehensive Cancer and Research Institute; Falls Church Virginia

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28554/fullpdf

Reference33 articles.

1. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy;Lima;AIDS,2007

2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators;Palella;N Engl J Med,1998

3. Elevated incidence of lung cancer among HIV-infected individuals;Engels;J Clin Oncol,2006

4. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007;Shiels;JAMA,2011

5. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy;Clifford;J Natl Cancer Inst,2005

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Disparities Between Patients with Breast Cancer With and Without HIV: A Research Framework;JCO Global Oncology;2023-04

2. The Kaposi’s sarcoma progenitor enigma: KSHV-induced MEndT–EndMT axis;Trends in Molecular Medicine;2023-03

3. Receptor tyrosine kinase inhibitors negatively impact on pro-reparative characteristics of human cardiac progenitor cells;Scientific Reports;2022-06-16

4. Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research;Translational Oncology;2021-09

5. Repurposing of Kinase Inhibitors for Treatment of COVID-19;Pharmaceutical Research;2020-08-10